LIBERATE-1, NCT05670379: Assessment of Safety, Tolerability and Drug Levels of NPM-119 in Participants With Type 2 Diabetes |
|
|
| Not yet recruiting | 1 | 16 | NA | NPM-119 (exenatide implant), Bydureon BCise (exenatide extended release) | Vivani Medical, Inc, Medpace, Inc. | Type 2 Diabetes | 01/25 | 01/25 | | |
